arcotatug tavetecan

Arcotatug tavetecan (IBI343) is a recombinant human monoclonal antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2). It consists of a humanized anti-CLDN18.2 IgG1 antibody conjugated to the topoisomerase I inhibitor payload, exatecan, via a protease-cleavable linker. The drug is designed to treat CLDN18.2-expressing tumors, particularly gastric and gastroesophageal junction adenocarcinomas, by binding to the target protein, internalizing, and releasing the cytotoxic payload to induce DNA damage and apoptosis. It also exhibits a bystander effect, allowing it to kill neighboring tumor cells. The drug is being developed by Innovent Biologics in collaboration with Takeda Pharmaceuticals.

Other names

arcotatug tavetecanIBI-343IBI343IBI 343